undamentalytics Newsletter

Staab Thomas R II: insider trades

Chief financial officer at 2 companies we cover. 1 open-market purchase and 9 sales not made under a pre-set plan, reported from March 7, 2014 to September 15, 2026.

Would copying Staab Thomas R II’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −37.9% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Staab Thomas R II: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 8 −26.4% −16.9% 75% 4 −1.50 0.23 No reliable evidence
Sales, 12 months after the report 8 −37.9% −26.9% 100% 4 −2.74 0.071 No reliable evidence
Sales, 12 months after the trade 7 −40.4% −32.0% 100% 3 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Biocryst Pharmaceuticals Inc BCRX Senior Vice President and CFO09March 7, 2014December 6, 2018
Tenax Therapeutics, Inc. TENX Chief Financial Officer10September 15, 2026September 15, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 15, 2026September 11, 2026 TENX Purchase $11,010 not yetnot yetnot yet
December 6, 2018December 4, 2018 BCRX Sale $37,063 −11.9%−91.7%−88.5%
August 15, 2016August 11, 2016 BCRX Sale $30,388 not yetnot yetnot yet
August 11, 2016August 9, 2016 BCRX Sale $64,576 +0.8%−24.5%not yet
December 22, 2015December 21, 2015 BCRX Sale $33,145 −73.4%−52.0%−51.5%
December 18, 2015December 17, 2015 BCRX Sale $31,470 −77.2%−51.5%−52.7%
December 31, 2014December 29, 2014 BCRX Sale $119,320 −21.8%−19.1%−14.4%
August 29, 2014August 27, 2014 BCRX Sale $135,800 −23.1%−10.2%−19.2%
March 17, 2014March 14, 2014 BCRX Sale $35,125 +1.0%−26.4%−24.5%
March 7, 2014March 4, 2014 BCRX Sale $38,070 −6.0%−27.4%−32.0%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Staab Thomas R II traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.